The present disclosure provides boron-containing diacylhydrazines having Formula I:
and the pharmaceutically acceptable salts and solvates thereof, wherein R
1
, R
2
, R
3
, R
4
, and R
5
are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.
本公开提供具有I式的含
硼二酰
肼化合物及其药学上可接受的盐和溶剂化物,其中R1、R2、R3、R4和R5的定义如规范中所述。本公开还提供了使用含
硼二酰
肼化合物的ecdysone受体
基础的诱导
基因表达系统。因此,本公开适用于
基因治疗、疾病治疗、大规模生产蛋白质和
抗体、基于细胞的筛选测定、功能
基因组学、蛋白质组学、代谢组学和调控转
基因生物的特征等应用,其中需要控制
基因表达
水平。